By Colin Kellaher
Essa Pharma's stock price plunged after the clinical-stage pharmaceutical company said it was throwing in the towel on its lead product candidate and exploring strategic alternatives.
Shares of the South San Francisco, Calif., company were down 63.5% at $1.90 in premarket trading Friday.
Essa late Thursday said it was ending Phase 2 study of masofaniten in prostate cancer after determining the study was unlikely to meet its primary endpoint.
The company said it would also terminate other studies involving masofaniten and launch a process to review strategic options focused on maximizing shareholder value.
Essa, which had a market capitalization of nearly $231 million based on Thursday's closing price of $5.20, said it had net working capital of $124.3 million as of Sept. 30.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 01, 2024 06:50 ET (10:50 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。